TORONTO, Jan. 21 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) and bioAnalytics Inc. announced today that the Dental Health Group in
Burlington, Ontario, has deployed the HeartFriendly Dentist™ program,
which utilizes the UFIT®TEN-10 Health Monitor.
"Our mandate for the HeartFriendly™ Dentist program is to support
patient health and help improve vital sign testing in dental care,"
stated Steve Colivas, President of bioAnalytics. "This testing may
assist dentists in detecting abnormal vital signs, such as high blood
pressure and irregular pulse, and in referring patients to physicians
as needed. We believe the UFIT®TEN-10, utilized at the point of care,
will eventually become a standard tool for every dental clinic and
assist in improving overall patient health".
Dentists are well-positioned to screen patients for hypertension and
other health conditions before providing dental treatment. Under the
HeartFriendly™ Dentist program, dental professionals use UFIT® TEN-10
to conduct a 60- second reading similar to that using a blood pressure
cuff. Test results include blood pressure statistics (systolic,
diastolic, and mean arterial pressure "MAP")) as well as pulse rate
average and variability. In addition, the UFIT®TEN-10 provides a
real-time tracing of the arterial pressure pulse. Dentists can use this
comprehensive information to better monitor the overall health of their
"Currently, our Dental Health Group services the dental needs of
approximately 11,000 Burlington-area residents. We have approximately
30 clinical staff who use the UFIT® TEN-10 to routinely take vital
signs of patients in our practice", stated Dr. Christian von Rosenbach,
one of the founding partners at Dental Health Group. "In this day and
age, when so many people are suffering from hypertension and other
chronic heart diseases, we have a responsibility to monitor our
patients' health. The Biosign UFIT® TEN-10 device gives us an excellent
tool with which we can assess a patient's cardiovascular status at the
time of treatment."
"The HeartFriendly™ Dentist program represents a substantial opportunity
for us to introduce Biosign's UFIT® services to over 65,000 dental
professionals and to the 23 million Canadians that consult them
annually," stated Peter Tassiopoulos, CEO of Biosign. "This program
also demonstrates how UFIT® supports segment-focused approaches to the
About bioAnalytics Inc.
bioAnalytics has developed the HeartFriendly™ Dentist program to provide
leading-edge, medical devices to dental professionals, allowing them to
measure and monitor their patients' vital signs easily, reliably, and
routinely. Please visit www.heartfriendlydentist.com
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com.
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
|Biosign Contact Information ||bioAnalytics Contact Information|
|Alan S. Roemer, SVP ||Steve Colivas, President|
|The Trout Group LLC ||bioAnalytics Inc.|
|Phone: 646 378-2900 ||Phone: 416.509.0330|
|Email : email@example.com ||Email : firstname.lastname@example.org|